We are live on ! Find out more
ULBI icon

Ultralife

63 hedge funds and large institutions have $38.9M invested in Ultralife in 2025 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 13 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 13

0.6% more ownership

Funds ownership: 33.72%34.31% (+0.6%)

0% more funds holding

Funds holding: 6363 (0)

0% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 12

23% less capital invested

Capital invested by funds: $50.4M → $38.9M (-$11.4M)

Holders
63
Holders Change
Holders Change %
0%
% of All Funds
0.82%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
12
Increased
22
Reduced
13
Closed
12
Calls
Puts
Net Calls
Net Calls Change

ULBI Hedge Fund Activity: Q3 2025 in Review

63 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Ultralife (ULBI) for Q3 2025, worth a combined $38.9M — down 23% from $50.4M a quarter earlier.

Fund positioning in ULBI was balanced in Q3 2025: 12 funds opened new positions, 12 closed out, 22 added to existing stakes and 13 trimmed.

The largest buyer was Arrowstreet Capital, adding an estimated $1.13M. The largest seller was Essex Investment Management, exiting entirely with an estimated $2.15M sold.

  • 63 institutional investors held Ultralife (ULBI) as of Q3 2025, unchanged from Q2 2025.
  • Funds reported $38.9M of Ultralife stock for Q3 2025, down 23% quarter-over-quarter.
  • 12 funds opened new Ultralife positions in Q3 2025 and 12 closed out, a net change of 0 holders.
  • The largest Ultralife buyer in Q3 2025 was Arrowstreet Capital, an estimated $1.13M added.
  • The largest Ultralife seller in Q3 2025 was Essex Investment Management, an estimated $2.15M sold.

Based on aggregated 13F filings for Q3 2025.